Elicio Therapeutics, Inc. (ELTX) - Dilution Analysis

10-Q filing | 18.2M shares outstanding

S-3/A filing: This is an S-3/A filing for Elicio Therapeutics, Inc. which discusses the potential offering of common stock and related underwriter activities such as short sales and stabilizing transactions.

10-K filing | 18.4M shares outstanding

10-Q filing | 16.7M shares outstanding

10-Q filing | 16.1M shares outstanding

8-K filing: Elicio Therapeutics, Inc. entered into a note purchase agreement with GKCC, LLC, issuing a Senior Secured Promissory Note for $10.0 million and a warrant to purchase 103,225 shares of common stock.

10-Q filing | 16.0M shares outstanding

10-K filing | 16.0M shares outstanding

8-K filing: Elicio Therapeutics issued 3,500,573 shares of common stock to GKCC, LLC on March 5, 2025, in satisfaction of a convertible note, resulting in 15,861,913 shares outstanding.

10-Q filing | 10.8M shares outstanding

S-3 filing: This S-3 filing registers the shares of common stock issuable upon conversion of a convertible note issued in August 2024.

10-Q filing | 11.3M shares outstanding

8-K filing: Elicio Therapeutics, Inc. completed an underwritten offering of shares of common stock and pre-funded warrants, along with common warrants, at a combined offering price of $5.00 per share and accompanying common warrant, and $4.99 per pre-funded warrant and accompanying common warrant, with net proceeds expected to be approximately $10.9 million. ($11.48M proceeds)

S-3/A filing: The filing relates to the resale of up to 2,245,702 shares of common stock by the selling stockholder, which consists of shares held by the selling stockholder and shares issuable upon the exercise of pre-funded warrants.

S-3 filing: Elicio Therapeutics, Inc. is offering up to $40,000,000 of common stock through an at-the-market offering via JonesTrading Institutional Services LLC.

10-Q filing | 10.3M shares outstanding

S-3 filing: Elicio Therapeutics, Inc. is filing an S-3 to register 1,213,000 shares of common stock for resale by the selling stockholder.

10-K filing | 10.2M shares outstanding

8-K filing: Elicio Therapeutics, Inc. entered into a Subscription Agreement with GKCC, LLC for the issuance and sale of pre-funded warrants to purchase up to 1,032,702 shares of common stock at a price of $5.81 per warrant, with gross proceeds of approximately $6.0 million. ($6.0M proceeds)

8-K filing: Elicio Therapeutics, Inc. sold 584,170 shares of its common stock under the "at-the-market" equity offering program for net sale proceeds of approximately $4.89 million since the quarter ended September 30, 2023. ($0.0M proceeds)

8-K filing: Elicio Therapeutics, Inc. entered into a Subscription Agreement with GKCC, LLC for the issuance and sale of 1,213,000 shares of common stock at $5.81 per share, resulting in gross proceeds of approximately $7.0 million, with the closing expected on December 22, 2023. ($7.0M proceeds)

10-Q filing | 8.4M shares outstanding

10-Q filing | 8.4M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 30,114,113 → 3,011,411

10-Q filing | 30.1M shares outstanding

10-K filing | 30.0M shares outstanding

10-Q filing | 30.1M shares outstanding

10-Q filing | 30.0M shares outstanding

10-Q filing | 30.0M shares outstanding

S-3 filing: Angion Biomedica Corp. may offer and sell up to an aggregate amount of $100,000,000 of any combination of common stock, preferred stock, debt securities and warrants from time to time, and may offer common stock under an At-the-Market Equity Offering Sales Agreement for up to $21,000,000.

10-K filing | 28.2M shares outstanding

10-Q filing | 29.8M shares outstanding

10-Q filing | 29.7M shares outstanding

10-Q filing | 29.7M shares outstanding

8-K filing: Angion Biomedica Corp. sold 1,562,500 shares of common stock to Vifor Pharma at $16.00 per share for gross proceeds of $25.0 million in a concurrent private placement, which closed on February 9, 2021, along with the Initial Public Offering of 5,750,000 shares of common stock at $16.00 per share. ($25.0M proceeds)

S-1/A filing: This S-1/A filing registers an offering of common stock, including an option for underwriters to purchase additional shares and a concurrent private placement.

S-1/A filing: S-1/A filing for an initial public offering of common stock with a concurrent private placement.

S-1 filing: This S-1 filing outlines a proposed initial public offering of common stock along with a concurrent private placement to fund clinical trials, research and development, and general corporate purposes.